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Abstract: Reactive oxygen species (ROS) play important roles in cell signaling and homeostasis.
However, an abnormally high level of ROS is toxic, and is implicated in a number of diseases. Positron
emission tomography (PET) imaging of ROS can assist in the detection of these diseases. For the
purpose of clinical translation of [18 F]6-(4-((1-(2-fluoroethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)5-methyl-5,6-dihydrophenanthridine-3,8-diamine ([18 F]DHMT), a promising ROS PET radiotracer,
we first manually optimized the large-scale radiosynthesis conditions and then implemented them in
an automated synthesis module. Our manual synthesis procedure afforded [18 F]DHMT in 120 min
with overall radiochemical yield (RCY) of 31.6% ± 9.3% (n = 2, decay-uncorrected) and specific
activity of 426 ± 272 GBq/µmol (n = 2). Fully automated radiosynthesis of [18 F]DHMT was achieved
within 77 min with overall isolated RCY of 6.9% ± 2.8% (n = 7, decay-uncorrected) and specific
activity of 155 ± 153 GBq/µmol (n = 7) at the end of synthesis. This study is the first demonstration
of producing 2-[18 F]fluoroethyl azide by an automated module, which can be used for a variety of
PET tracers through click chemistry. It is also the first time that [18 F]DHMT was successfully tested
for PET imaging in a healthy beagle dog.
Keywords: PET; reactive oxygen species; in vivo imaging; automation; 2-[18 F]fluoroethyl azide;
translational study

1. Introduction
Reactive oxygen species (ROS) are chemically reactive species, such as singlet oxygen, hydrogen
peroxide, hydroxyl radicals and superoxide. ROS are involved in cell signaling which is important
in the maintenance of cell homeostasis [1]. However, a sustained high level of ROS is detrimental
and believed to be associated with diseases such as cancer [2,3], ischemic heart disease [4] and
chemotherapy-induced cardiotoxicity [5]. Development of ROS imaging probes will enable the
monitoring of ROS levels in vivo.
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As a non-invasive technique, positron emission tomography (PET) imaging of ROS can assist in
As a non-invasive technique, positron emission tomography (PET) imaging of ROS can assist in
the detection of ROS levels in living subjects. There are several radiotracers reported for ROS imaging
the detection of ROS levels in living subjects. There are several radiotracers reported for ROS imaging
with PET, such as [11C]ascorbic acid [6], peroxy-caged-[18F]fluorodeoxy thymidine-1 (PC-FLT-1) [7],
with PET, such as [11 C]ascorbic acid [6], peroxy-caged-[18 F]fluorodeoxy thymidine-1 (PC-FLT-1) [7],
and the dihydroquinoline derivatives [11C]DHQ1 [8] and [18F]DHMT [9]. Among them, [18F]DHMT,
and the dihydroquinoline derivatives [11 C]DHQ1 [8] and [18 F]DHMT [9]. Among them, [18 F]DHMT,
[11C]DHQ1, and [11C]ascorbic acid have been tested in rodents. However, the short half-life (20 min)
[11 C]DHQ1, and [11 C]ascorbic acid have been tested in rodents. However, the short half-life (20 min)
of carbon-11 limits the [11C]-labeled tracers from widespread clinical applications, as they require an
of carbon-11 limits the [11 C]-labeled tracers from widespread clinical applications, as they require
on-site cyclotron for production. Alternately, [18F]DHMT is more advantageous, not only in that the
an on-site cyclotron for production. Alternately, [18 F]DHMT is more advantageous, not only in that
longer half-life of fluorine-18 permits off-site production and transportation to multiple clinics, but
the longer half-life of fluorine-18 permits off-site production and transportation to multiple clinics, but
also in that it can be selectively oxidized by superoxide and trapped in the cell irreversibly [9].
also in that it can be selectively oxidized by superoxide and trapped in the cell irreversibly [9].
The usefulness of [18F]DHMT as an ROS imaging agent has been shown in the detection of
The usefulness of [18 F]DHMT as an ROS imaging agent has been shown in the detection of
doxorubicin-induced cardiotoxicity in a rodent model [9]. However, in the study only small-scale
doxorubicin-induced cardiotoxicity in a rodent model [9]. However, in the study only small-scale
production of [18F]DHMT was reported (starting from 1.9 GBq of [18F]fluoride). It is challenging to
production of [18 F]DHMT was reported (starting from 1.9 GBq of [18 F]fluoride). It is challenging to
scale up the production to make a large batch for multiple clinical doses, as the product is sensitive to
scale up the production to make a large batch for multiple clinical doses, as the product is sensitive to
radiolysis. Following the reported method, oxidation of the product was observed during the HPLC
radiolysis. Following the reported method, oxidation of the product was observed during the HPLC
purification and formulation processes. In order to translate it to clinical investigations, we developed
purification and formulation processes. In order to translate it to clinical investigations, we developed
a robust and fully automated radiosynthesis of [18F]DHMT, which consistently yielded the product
a robust and fully automated radiosynthesis of [18 F]DHMT, which consistently yielded the product in
in large quantity, and with quality suitable for human use. PET imaging of the heart of a healthy beagle
large quantity, and with quality suitable for human use. PET imaging of the heart of a healthy beagle
dog was also performed using [18F]DHMT. Dogs were chosen because they have been shown to be the
dog was also performed using [18 F]DHMT. Dogs were chosen because they have been shown to be the
ideal large animal for modeling human cardiotoxicity with similar chemotherapy doses [10–12].
ideal large animal for modeling human cardiotoxicity with similar chemotherapy doses [10–12].
2. Results
2.
Results
2.1. Manual Radiosynthesis under Optimized Conditions
18F]DHMT was synthesized manually in high yield via a
[18
F]DHMT was synthesized manually in high yield
two-step, two-pot reaction sequence
modified from the previously
previously described
described method
method (Scheme
(Scheme 1)
1) [9].
[9]. The
The first
first step
step was to prepare
18F]fluoroethyl azide ([18
18
18
2-[ F]fluoroethyl azide F]2)
F]2)from
from 2-azidoethyl
2-azidoethyl tosylate
tosylate (1).
(1). In
In the
the manual synthesis, consistently
18F]2,
radiochemical yield
yield (RCY)
(RCY)of
of79%
79%±
± 8% (n == 3,
high isolated radiochemical
3, decay
decay corrected) was obtained for [18
F]2,
2.2.2
,
5.6
mg),
using 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane
4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (Kryptofix
2.2.2
or
K
(Kryptofix 2.2.2
2.2.2 , 5.6
18F]fluoride at 90 °C
◦ C for 10 min. It was purified
carbonate (K
(K22CO33,, 1 mg), and anhydrous [18
potassium carbonate
F]fluoride
N,N-dimethylformamide (DMF,
by passing through two stacked SepPak cartridges, eluted off with N,N-dimethylformamide
(DMF,
reaction.
0.5 mL), and used for the second step reaction.

18F]DHMT radiosynthesis.
Scheme 1.
1. Reaction scheme
scheme for
for [[18
Scheme
F]DHMT

18F]DHMT
Subsequently, Cu(I)-catalyzed
Cu(I)-catalyzed click
click chemistry
chemistry was
was used
used to
to construct
construct the
the triazole
triazole unit
unit of
of[[18
Subsequently,
F]DHMT
([18F]5).
([
F]5). Using
Using aa commercially
commercially available
available Cu(I)-stabilizing
Cu(I)-stabilizing ligand,
ligand, tris[(1-benzyl-1H-1,2,3-triazol-4-yl)
tris[(1-benzyl-1H-1,2,3-triazol-4-yl)
methyl]amine (TBTA),
thethe
click
reaction
proceeded
smoothly
in a solvent
ethanol, ammonium
methyl]amine
(TBTA),
click
reaction
proceeded
smoothly
in amixture
solventofmixture
of ethanol,
acetate
buffer
(pH
=
7),
and
DMF
(6/9/51,
v/v/v),
with
88%
±
3%
(decay
corrected,
n
=
2)
conversion
ammonium acetate buffer (pH = 7), and DMF (6/9/51, v/v/v), with 88% ± 3% (decay corrected, n = to
2)
the final product. No formation of byproducts was observed. The crude mixture was purified by
18
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conversion to the final product. No formation of byproducts was observed. The crude mixture was
purified
by semi-preparative
high-performance
liquid chromatography
Figure
1a,forretention
semi-preparative
high-performance
liquid chromatography
(HPLC, Figure(HPLC,
1a, retention
time
[18F]5:
18
time
for
[
F]5:
16–18
min),
and
formulated
for
intravenous
injection.
16–18 min), and formulated for intravenous injection.

Figure 1. Semi-preparative radio-HPLC chromatograms for purification of [18F]DHMT ([18F]5).
Figure 1. Semi-preparative radio-HPLC chromatograms for purification of [18 F]DHMT ([18 F]5).
(a) Manual method; (b) Automated method.
(a) Manual method; (b) Automated method.

2.2. Automated Radiosynthesis of [18F]DHMT
2.2. Automated Radiosynthesis of [18 F]DHMT
Fully automated radiosynthesis of [18F]DHMT with [18F]2 was achieved within 77 min. The overall
Fully automated
radiosynthesis
of [18
F]DHMT
with [18 F]2 was nachieved
within
77 min.
was 6.9%
± 2.8%
(decay-uncorrected,
= 7), starting
from
63 toThe
107 overall
GBq
isolated
RCY of [18F]DHMT
18
isolated
RCY
of
[
F]DHMT
was
6.9%
±
2.8%
(decay-uncorrected,
n
=
7),
starting
from
63
to
107
GBq
18
of [ F]fluoride. Specific activity was 155 ± 153 GBq/µmol (n = 7) at the end of synthesis.
of [18 F]fluoride. Specific activity was 155 ± 153 GBq/µmol (n = 7) at the end of synthesis.
2.3. Quality Control and Stability Tests of [18F]DHMT
2.3. Quality Control and Stability Tests of [18 F]DHMT
Quality control results from large-scale productions of [18F]DHMT are shown in Table 1. The product
Quality
results
from
large-scale
[18 F]DHMT
are of
shown
in Table
solution
wascontrol
clear and
colorless,
with
pH of aboutproductions
7 (n = 9). The of
radiochemical
purity
[18F]DHMT
was 1.
± 1.9%
(n = 9).was
Theclear
radionuclide
identity
was
determined
the radioactivepurity
decay of
The96.3%
product
solution
and colorless,
with
pH
of about 7by
(nmeasuring
= 9). The radiochemical
half-life of was
[18F]DHMT,
± 3.9radionuclide
min (n = 9) and
consistent
the half-life
fluorine-18.the
[18 F]DHMT
96.3% ±which
1.9%was
(n =110.2
9). The
identity
waswith
determined
byof
measuring
One typical
production
[18F]DHMT
waswas
checked
the (n
quality
control
tests required
radioactive
decay
half-lifebatch
of [18of
F]DHMT,
which
110.2with
± 3.9allmin
= 9) and
consistent
with the
18
for
human
use.
For
this
production,
levels
of
residual
solvents
and
K
2.2.2
were
below
the
levels
by
half-life of fluorine-18. One typical production batch of [ F]DHMT was checked with all theset
quality
the
US
FDA
and
results
for
other
tests
all
met
the
specifications
for
human
use.
control tests required for human use. For this production, levels of residual solvents and K2.2.2 were
below the levels set by the US FDA and results for other tests all met the specifications for human use.
Table 1. Quality control results of [18F]DHMT.
18

Table 1. QualityRelease
control results
of for
[ F]DHMT.
Test
Criteria
Human Use
Visual inspection (n = 9)
Clear, colorless
Test pH (n = 9)
Release Criteria4.5–8.5
for Human Use
Solution
Residual
solvent(n
test
(n = 1)
MeCN < 0.41
mg/mL,
DMF < 0.88 mg/mL
Visual
inspection
= 9)
Clear,
colorless
Solution
4.5–8.5mg/mL
K2.2.2pH
test(n(n==9)1)
<0.05
Residual
solvent test
test (n
MeCN < 0.41 mg/mL,
< 0.88 mg/mL
Endotoxin
(n == 1)
1)
<17.5DMF
EU/mL
K2.2.2 test (n = 1)
<0.05 mg/mL
Sterile filter integrity test (n = 1)
Bubble point pressure > 50 psi
Endotoxin test (n = 1)
<17.5 EU/mL
Sterility
test
(n
=
1)
No bacterial
Sterile filter integrity test (n = 1)
Bubble point
pressuregrowth
> 50 psi
Radiochemical
purity
(n
=
9)
>90%
Sterility test (n = 1)
No bacterial
growth
Radionuclidepurity
identity
Measured t1/2 between
98.8 to 128.8 min
Radiochemical
(n =(n9)= 9)
>90%

Result
Clear, colorless
Result
7
Clear, Pass
colorless
7
Pass
<5Pass
EU/mL
Pass
Pass
<5 EU/mL
Pass
Pass
96.3%
± 1.9%
Pass
110.2 ±±3.5
min
96.3%
1.9%
Radionuclide identity (n = 9)
Measured t1/2 between 98.8 to 128.8 min
110.2 ± 3.5 min
The identity of [18F]DHMT was confirmed by co-injection of the final radioactive product with
theThe
non-radioactive
and co-elution
of the UVof
and
peaks on
the HPLC
identity of [18reference
F]DHMTstandard,
was confirmed
by co-injection
theradioactive
final radioactive
product
with
chromatogram (Figure 2). Moreover, stability test for [18F]DHMT produced using either the manual
the non-radioactive reference standard, and co-elution of the UV and radioactive peaks on the HPLC
or automated method indicated that the radiochemical purity was maintained above 90% at 6 h after
chromatogram (Figure 2). Moreover, stability test for [18 F]DHMT produced using either the manual or
the end of synthesis.
automated method indicated that the radiochemical purity was maintained above 90% at 6 h after the
end of synthesis.
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Figure 2. Analytical HPLC chromatograms for [18F]DHMT: (a) radioactivity detection; (b) UV, with

Figure 2. Analytical19HPLC chromatograms for [18 F]DHMT: (a) radioactivity detection; (b) UV, with
co-injection of [ F]DHMT.
co-injection of [19 F]DHMT.
2.4. Comparison of Three Methods for Radiosynthesis of [18F]DHMT

2.4. Comparison of Three Methods for Radiosynthesis of [18 F]DHMT

Table 2 shows summary of the three methods for [18F]DHMT radiosynthesis. Our modified manual
synthesis
procedure
afforded
F]DHMT
a total synthesis
of about
120 min, with overall
Table
2 shows
summary
of[18the
threeinmethods
for [18 time
F]DHMT
radiosynthesis.
Our RCY
modified
18
18
of synthesis
31.6%
± 9.3%
(n = 2, decay-uncorrected,
based
starting
[18radioactivity
F]fluoride
activity
100–101
GBq)min,
and with
Figure
2. procedure
Analytical
HPLC
chromatograms
for [on
F]DHMT:
(a)
detection;
UV, with
manual
afforded
[ F]DHMT
in a total
synthesis
time of
of(b)
about
120
19F]DHMT.
activity
of
± 272(n
GBq/µmol
(n = 2) at the end ofbased
synthesis.
automated
radiosynthesis,
of ±
[426
overallspecific
RCYco-injection
of
31.6%
9.3%
= 2, decay-uncorrected,
on For
starting
[18 F]fluoride
activity of
[18F]DHMT was prepared in a total synthesis time of about 77 min. More than 4.44 GBq of the final
100–1012.4.
GBq)
and specific
activity
offor
426
± 272 GBq/µmol
(n = 2) at the end of synthesis. For automated
Comparison
of Threewith
Methods
Radiosynthesis
F]DHMT
product
was obtained,
specific
activity of 155of±[18153
GBq/µmol (n = 7) at the end of synthesis. We
radiosynthesis, [18 F]DHMT was prepared in a total synthesis time of about 77 min. More than 4.44 GBq
foundTable
a decrease
insummary
RCY (6.9%
± 2.8%,
= 7, decay-uncorrected)
for automated
synthesis
2 shows
of the
threenmethods
for [18F]DHMT radiosynthesis.
Our
modifiedcompared
manual
of the with
finalmanual
product
was obtained,
with specific
activity
of 155 ± 153
GBq/µmol
(n =[7)
at the end of
18F]DHMT
synthesis.
The
semi-preparative
HPLC
chromatogram
for
the
purification
18
synthesis procedure afforded [ F]DHMT in a total synthesis time of about 120 min, with of
overall
RCY
18F]2 left
synthesis.
We
found
a
decrease
in
RCY
(6.9%
±
2.8%,
n
=
7,
decay-uncorrected)
for
automated
synthesis
18
inofan
automated
synthesis
(Figure
1b)
also
confirmed
that
there
was
more
[
unreacted
when
31.6% ± 9.3% (n = 2, decay-uncorrected, based on starting [ F]fluoride activity of 100–101 GBq) and
18
compared
with
manual
synthesis.
The
semi-preparative
HPLC
chromatogram
for
the
purification
F]DHMT
was
compared
with
manual
synthesis.
For
manual
and
automated
radiosynthesis,
[
specific activity of 426 ± 272 GBq/µmol (n = 2) at the end of synthesis. For automated radiosynthesis,
produced
with
radiochemical
of 93.9%
± 0.6%
(n
=also
2)77
and
96.9%
± 1.7%
(n
=there
7),
respectively.
[18F]DHMT
prepared
in apurity
total
synthesis
time
of1b)
about
min.
More
than
4.44
GBq
of
the more
final [18 F]2
of [18 F]DHMT
inwas
an
automated
synthesis
(Figure
confirmed
that
was
product
was
obtained,
with
specific
activity
of
155
±
153
GBq/µmol
(n
=
7)
at
the
end
of
synthesis.
We
left unreacted when compared with manual synthesis. For manual and
automated radiosynthesis,
18F]DHMT.
Table
2.
Comparison
of
three
methods
for
radiosynthesis
of
[
found
a
decrease
in
RCY
(6.9%
±
2.8%,
n
=
7,
decay-uncorrected)
for
automated
synthesis
compared
[18 F]DHMT was produced with radiochemical purity of 93.9% ± 0.6% (n = 2) and
96.9% ± 1.7%
with manual synthesis. The semi-preparative HPLC chromatogram for the purification of [18F]DHMT
Radiochemical
Specific
Activity
Synthesis
(n = 7), in
respectively.
Method
RCY * 1b)
(%)also confirmed that there was more [18F]2 left unreacted when
an automated
synthesis (Figure
Purity (%)
(GBq/µmol)
Time (min)
compared with manual synthesis. For manual and automated radiosynthesis,
[18F]DHMT was
18
Literature
[9]
42.8
90–100
13–24
Table 2. Comparison of three methods for radiosynthesis of [ F]DHMT. 120
produced with radiochemical purity of 93.9% ± 0.6% (n = 2) and 96.9% ± 1.7% (n = 7), respectively.
Manual (n = 2)
31.6 ± 9.3
93.9 ± 0.6
426 ± 272
~120
Automated (n
=
7)
6.9
±
2.8
96.9
±
1.7
155
±
153
~77
Radiochemical
Specific 18Activity
Synthesis
Table 2.RCY
Comparison
Method
* (%) of three methods for radiosynthesis of [ F]DHMT.18
Purity
(%)
(GBq/µmol)
Time (min)
* Decay-uncorrected RCY calculated based
on the
isolated product
and starting [ F]fluoride.
Radiochemical
Specific Activity
Synthesis
Method
RCY * (%)
Literature
[9]
42.8
90–100
13–24
120
Purity
(%)
(GBq/µmol)
Time
(min)
2.5.Manual
Animal (n
Imaging
= 2)
31.6 ± 9.3
93.9 ± 0.6
426 ± 272
~120
Literature
90–100
13–24
120 ~77
Automated
(n Figure
= 7) [9] 3 are
6.9transverse,
± 42.8
2.8
96.9
± sagittal
1.7
± images
153
Shown
in
and
slices 426
of155
PET
obtained
from 60 to
Manual
(n = 2)
31.6 ± 9.3 coronal93.9
± 0.6
± 272
~120
18F]DHMT
* Decay-uncorrected
RCY calculated
based on
the
isolated
product
and starting
[18 F]fluoride.
90 min Automated
after
intravenous
injection
of
[
in
a
beagle
dog.
The
images
exhibited
high
myocardial(n = 7)
6.9 ± 2.8
96.9 ± 1.7
155 ± 153
~77
to-background
ratios, especially
in the left
ventricle.
The standardized
uptake[18F]fluoride.
value ratio was 2.3
* Decay-uncorrected
RCY calculated
based
on the isolated
product and starting
2.5. Animal
Imaging
between
the left ventricle and the blood pool, and 0.14 between the left ventricle and the liver. The
right
ventricle
and papillary muscle were also clearly visible.
2.5. Animal
Imaging

Shown in Figure 3 are transverse, coronal and sagittal slices of PET images obtained from
Figure 3 are transverse,
and sagittal
of PET
images
60 to
60 to 90 minShown
afterinintravenous
injection coronal
of [18 F]DHMT
inslices
a beagle
dog.
Theobtained
imagesfrom
exhibited
high
90 min after intravenous injection of [18F]DHMT in a beagle dog. The images exhibited high myocardialmyocardial-to-background ratios, especially in the left ventricle. The standardized uptake value ratio
to-background ratios, especially in the left ventricle. The standardized uptake value ratio was 2.3
was 2.3 between
betweenthe
the
ventricle
the blood
pool,
and
0.14 between
the leftand
ventricle
and
leftleft
ventricle
and and
the blood
pool, and
0.14
between
the left ventricle
the liver.
Thethe liver.
The right
ventricle
muscle
were
clearly
visible.
right
ventricleand
and papillary
papillary muscle
were
alsoalso
clearly
visible.

Figure 3. Representative [18F]DHMT PET images of the heart in a beagle dog.

Figure 3. Representative [18F]DHMT PET images of the heart in a beagle dog.

Figure 3. Representative [18 F]DHMT PET images of the heart in a beagle dog.
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We have carried out multiple imaging studies with high specific activity [18 F]DHMT, with injection
mass of 1.05 ± 0.84 µg (n = 9). No adverse effects from the radiotracer were observed. Data analyses
for PET imaging of healthy and diseased beagle dog models with [18 F]DHMT are underway and the
results will be published elsewhere.
3. Discussion
The ROS radiotracer [18 F]DHMT was synthesized manually in high yield and with high specific
activity via a two-step, two-pot reaction sequence. In our hands, the click reaction using copper(II)
sulfate (CuSO4 ) and sodium ascorbate as reported in the literature failed to yield the desired product
consistently. In addition, oxidation of the product during HPLC purification and post-processing was
also observed. We optimized the synthesis of [18 F]DHMT for a more consistent and reliable production,
and successfully adapted it to a commercially available automated synthesis module.
The first step concerned the preparation of 2-[18 F]fluoroethyl azide ([18 F]2). We used a recently
developed solid-phase extraction method instead of vacuum distillation to purify [18 F]2. This solid-phase
extraction method used two connected SepPak cartridges in series. [18 F]2 was selectively trapped
on the second cartridge, and eluted out for the second step reaction. The isolated yield of [18 F]2 was
similar to that reported (ca. 80%). This purification method is simple and reproducible, and thus
particularly suitable for implementation in the automated production of 18 F-labeled PET probes using
[18 F]2 [13].
For the click reaction, it failed to yield the desired product consistently when we employed CuSO4
and sodium ascorbate as reported in the literature, probably due to the facile disproportionation of
Cu(I) in aqueous solution to Cu(II) and its colloid, followed by oxidation of the product by Cu(II).
In Cu-catalyzed alkyne-azide click reactions, Cu(I)-stabilizing ligands are preferred for their high
efficiency during synthesis. TBTA is a commonly used and commercially available Cu(I)-stabilizing
ligand. We used a cocktail of TBTA, CuSO4 , N,N-di-isopropylethylamine (DIEA), and sodium ascorbate
in the subsequent click reaction, which resulted in a highly efficient conversion and minimal formation
of the oxidized byproduct.
ROS are generated by the ionizing radiation of radiolabeled products. [18 F]DHMT is susceptible
to ROS and radiolysis, which can irreversibly oxidize it to its inactive form. Therefore, it is important
to reduce or eliminate radiolysis, which is challenging for large-scale production. In the previously
published work, a starting radioactivity of 1.9 GBq [18 F]fluoride was used and the involvement of
radiolysis was not obvious. We found significant radiolysis of the product when we scaled up the
production with large amount of starting [18 F]fluoride (more than 63 GBq). Different HPLC purification
conditions were investigated to minimize oxidation and radiolysis of the final product during the
process, and to make the radiosynthesis of [18 F]DHMT more robust and reliable for routine large-scale
production. We found that addition of ascorbic acid [14,15] to the semi-preparative HPLC solvent and
formulation solution prevented radiolysis during purification and formulation of the product.
We implemented the modified steps in two runs of [18 F]DHMT using manual operations.
The isolated yields of [18 F]DHMT after semi-preparative HPLC and solid-phase extraction were
slightly lower than those reported previously (40.9% and 22.3% vs. 42.8%). The radiochemical purity
of the final product was 93.5% and 94.3%, respectively (Table 2).
We then translated the two-pot, two-step synthesis of [18 F]DHMT to a fully automated module.
All steps, including the initial receiving, eluting and drying of [18 F]fluoride from cyclotron target
water, direct 18 F-fluorination to form [18 F]2, SepPak purification of [18 F]2, [18 F]DHMT formation
by click reaction and, finally, preparative HPLC for product isolation, were successfully adapted to
the TRACERLab® FXN Pro module (GE Healthcare, Milwaukee, WI, USA). Manual radiosynthesis
of [18 F]2 has been reported previously [16,17]. However, the isolation method for [18 F]2 involved
distillation, which cannot be readily implemented in automated modules. Only one paper has reported
a two-step, one-pot method for automated production using [18 F]2. However, this two-step one-pot
approach requires a large amount of alkyne precursors [18]. As mentioned above, we used a recently
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developed solid-phase extraction method to isolate [18 F]2, which is amenable to adaptation in an
automated process. To implement this method, we added a second SepPak between VX1 and VX3
in the module as indicated in Figure 4. To the best of our knowledge, this is the first report of
implementing this solid-phase extraction method in an automated module for the purification and
isolation of [18 F]2 for use in subsequent click chemistry. Our method can be widely applied to other
automated radiosynthesis via the alkyne-azide click reaction with [18 F]2.
Quality control results revealed that the [18 F]DHMT product met all the current requirements
of a radiotracer for human use (Table 1). Our methods produced [18 F]DHMT in consistently high
radiochemical purity, and with specific activity higher than that reported in the literature (Table 2).
The final product from both manual and automated synthesis was stable, maintaining a radiochemical
purity of more than 95% after 6 h from the end of synthesis. We found a high degree of variability
in the specific activity of the final product. The water in the [18 F]fluoride transfer line appeared to
be the main factor for this variability. When the transfer line from the cyclotron to the module was
cleaned and dried immediately before the radiosynthesis, a high specific activity product was obtained.
When it was not cleaned and dried, a lower specific activity resulted.
A decrease in the RCY of [18 F]DHMT was found when transitioning from manual to automated
synthesis (6.9% ± 2.8%, n = 7, Table 2). The possible explanation for this is that a larger volume of
DMF was used to elute [18 F]2 from the SepPak, which diluted the concentrations of the reactants in
the second reactor, resulting in a less efficient click reaction. Nonetheless, the quantity of isolated
[18 F]DHMT from the automated method was sufficient for clinical applications.
Previously, [18 F]DHMT has been validated for ROS detection through in vitro assays and in vivo
imaging studies in rodents. In this study, we further applied this tracer to a large animal model. The dog
images showed high myocardial-to–blood pool ratios with reasonable liver uptake. These ratios are
similar to those obtained from previous studies in mice [9]. Our probe is an analog of dihydroethidium,
which has been widely used for fluorescence-based detection of superoxide. Therefore, [18 F]DHMT
may have properties similar to those of dihydroethidium, such as oxidation by heme proteins.
This could be the major route of probe oxidation in cardiac cells expressing high levels of heme
proteins [19]. Thus, the baseline radiotracer uptake in the dog heart may be attributed to its oxidation by
heme proteins. However, [18 F]DHMT can still be used for detecting doxorubicin-induced cardiotoxicity,
where ROS levels increase significantly in the heart [20].
Another point worth noting is that, as an analog of ethidium bromide, DHMT may display similar
toxicity as ethidium bromide. Nonetheless, PET imaging with [18 F]DHMT involves microdosing,
with trace amount of injected mass, and toxicological effects from the radiotracer are not expected.
As a matter of fact, we have carried out multiple imaging experiments in beagle dogs with injected
mass dose of 1.05 ± 0.84 µg (n = 9) and no adverse effects were observed.
In summary, we have optimized the large-scale radiosynthesis of [18 F]DHMT, transferred it to
a commercially available automated synthesis module, and demonstrated the feasibility of using
[18 F]DHMT for PET imaging of the heart in a canine model. Future studies with this radiotracer will
include its use in the detection of doxorubicin-induced cardiotoxicity.
4. Materials and Methods
4.1. General
All chemicals used were at least of analytical grade and obtained from commercial sources,
unless otherwise specified. The reference standard and respective precursor for [18 F]DHMT were
synthesized following published procedures [9]. [18 F]Fluoride was produced via the 18 O(p, n) 18 F
nuclear reaction by irradiation of [18 O]H2 O (Huayi Isotopes, Toronto, ON, Canada) in a GE PETtrace
cyclotron (GE Medical Systems, Uppsala, Sweden) with 16.5 MeV proton beam. Anion exchange
Chromafix cartridges (PS-HCO3 ) for [18 F]fluoride trapping were purchased from Macherey-Nagel
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(Dueringen, Germany). Solid-phase extraction cartridges (SepPak® Light C18, SepPak® Plus tC18 and
Oasis® Plus HLB) were purchased from Waters Associates (Milford, MA, USA).
The semi-preparative HPLC system was composed of a Shimadzu LC-20A pump (Shimadzu
Corp., Kyoto, Japan) equipped with a Knauer K200 UV detector (Knauer Wissenschaftliche Geräte
GmbH, Berlin, Germany), set at 254 nm, and a Bioscan radioactivity detector with Phenomenex
Luna C18 (2) column (10 µm, 250 × 10 mm). Semi-preparative HPLC mobile phase was made of
35% MeCN and 65% 0.1 M ammonium formate with ascorbic acid (0.3 g/L). The flow rate was
at 5 mL/min. The analytical HPLC system included a Shimadzu LC-20A pump equipped with
a SPD-M20A Photodiode Array (PDA) detector (Shimadzu Corp., Kyoto, Japan) or a SPD-20A UV/Vis
detector set at 234 nm, a Bioscan flow-through radioactivity detector, and a Genesis C18 column (4 µm,
250 × 4.6 mm). Analytical HPLC mobile phase was 33% MeCN and 67% 0.1 M ammonium formate
with 0.5% acetic acid (pH 4.2) at a flow rate of 2 mL/min.
4.2. Radiochemistry
4.2.1. Manual Radiolabeling of [18 F]DHMT under Optimized Reaction Conditions
Deprotection of 3 to Prepare Precursor 4
Under an argon atmosphere di-tert-butyl (5-methyl-6-(4-(prop-2-yn-1-yloxy)phenyl)-5,6dihydrophenanthridine-3,8-diyl)dicarbamate (3, 2 mg, 3.51 µmol) in CH2 Cl2 (100 µL) was added
to a solution of ascorbic acid (1 mg, 5.68 µmol) in TFA (100 µL, 1.3 mmol) and deionized (DI) water
(10 µL) in a 2 mL borosilicate glass V-vial wrapped with aluminum foil. After mixing, the reaction was
allowed to proceed at ambient temperature for 15 min, with brief vortexing every 5 min. The solvents
were dried under vacuum or argon stream at ambient temperature to afford 4 as a pale yellow solid,
which was then dissolved with a solution of DIEA in DMF (200 µL, DIEA/DMF = 1/10, v/v) to form
a pink solution for use in the click reaction with [18 F]2.
Preparation of Cu(I) Catalyst
A solution of CuSO4 -TBTA was prepared by mixing CuSO4 (0.4 M in 0.1 M ammonium acetate,
pH = 7, 30 µL) and TBTA (0.3 M in DMF, 40 µL). The Cu(I) catalyst was prepared by mixing freshly
dissolved sodium ascorbate (18 mg, 91 µmol) in water/ethanol (1:1, v/v, 120 µL) with the above
CuSO4 -TBTA solution to form a brown slurry which turned to a colorless solution upon mixing at
ambient temperature.
Preparation of 2-[18 F]fluoroethyl azide ([18 F]2)
Preparation of [18 F]2 followed the literature procedures [13]. Cyclotron-produced [18 F]fluoride in
was trapped on a PS-HCO3 anion-exchange cartridge pre-activated with ethanol (5 mL),
DI water (5 mL) and dried by air. The trapped [18 F]fluoride (100–101 GBq) was eluted slowly with
1 mL of K2.2.2 (5.6 mg)/potassium carbonate (1 mg) solution in MeCN/water (70/30, v/v) into a 2 mL
borosilicate glass V-vial. The eluent was dried at 110 ◦ C under argon, followed by azeotropic drying
with three 1.0 mL portions of anhydrous MeCN. Compound 1 (1.5–2.0 mg) in 0.2 mL anhydrous MeCN
was then added, followed by heating for 10 min at 90 ◦ C with occasional shaking.
After cooling in ice-water (0 ◦ C) for 1 min, the reaction mixture was diluted with DI water (10 mL)
and then passed through two stacked SepPak cartridges (a SepPak® Plus tC18 cartridge and an Oasis®
Plus HLB cartridge, both pre-activated by washing with 10 mL of EtOH followed by 10 mL of DI water).
The cartridges were rinsed with DI water (10 mL × 2). The Waters Oasis® Plus HLB cartridge was
taken off, dried with air, inverted, then eluted with DMF (3 × 0.5 mL) to collect [18 F]2. The first portion
of 0.5 mL DMF was discarded, and the second portion of 0.5 mL DMF was used for the click reaction.
[18 O]water
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Click Reaction to Form [18 F]DHMT ([18 F]5)
The solution of [18 F]2 in DMF (0.5 mL) was added to a V-vial preloaded with a solution of 4
(3.51 µmol) in 200 µL of DIEA/DMF (1/10, v/v). The Cu(I) catalyst as prepared above was added
to the V-vial via a syringe and the reaction was carried out at ambient temperature for 10 min with
occasional
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Reaction Sequence
The optimized manual synthesis procedures for [18F]DHMT were transferred to an automated
module (Figure 4). Synthetic protocol started with the delivery of aqueous [18F]fluoride to the synthesis
module. [18F]fluoride was trapped on an 18F separation cartridge (F18 SEP) and eluted into the first
reactor (RV1, 12) with a solution of K2.2.2/K2CO3 (Vial 1). Azeotropic drying was performed under
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Reaction Sequence
The optimized manual synthesis procedures for [18 F]DHMT were transferred to an automated
module (Figure 4). Synthetic protocol started with the delivery of aqueous [18 F]fluoride to the synthesis
module. [18 F]fluoride was trapped on an 18 F separation cartridge (F18 SEP) and eluted into the first
reactor (RV1, 12) with a solution of K2.2.2 /K2 CO3 (Vial 1). Azeotropic drying was performed under
reduced pressure at 70 ◦ C for 10 min and a steady stream of argon. The addition of 1 mL MeCN from
Vial 2 and subsequent drying at 100 ◦ C for 5 min was repeated twice. After drying, the solution of
compound 1 (Vial 3) was added into RV1 and heated at 85 ◦ C for 15 min to form [18 F]2. After cooling
down to 35 ◦ C, 18 mL of DI water (Vial 5) was added and the content in RV1 was passed through the
two SepPak cartridges (14 and 13) sequentially, followed by washing with 5 mL of DI water (Vial 4).
The intermediate was eluted off SepPak 13 with 1 mL of DMF (Vial 6) into the second reactor (RV2, 15).
The precursor 4 in 0.2 mL of DIEA/DMF (Vial 7) was added and the reaction was carried out at ambient
temperature for 10 min. The crude reaction solution was transferred to Vial 16 and loaded onto the
semi-preparative HPLC system for purification.
The desired product fraction was collected in a round bottom flask (Vial 18), diluted with 15 mL
of aqueous ascorbic acid solution (0.57 mM), and passed through a SepPak® Light C18 cartridge
(17). The cartridge was washed with 10 mL of aqueous ascorbic acid solution (0.57 mM) from Vial 43.
The product was eluted off the SepPak with a solution of ascorbic acid (1 mg) in USP grade absolute
ethanol (1 mL) (Vial 42), followed by 3 mL of USP grade saline (Vial 41), into the Product Vial 19, which
was preloaded with 7 mL of USP grade saline and 200 µL of sodium bicarbonate aqueous solution
(4.2%). Terminal sterilization was performed by passing the final formulated solution in the Product
Vial through a 0.22 µm sterile membrane filter into a sterile Dose Vial (Vial 20).
4.3. Quality Control and Stability Test
Visual inspection of [18 F]DHMT ([18 F]5) was done behind a shielded L-block. The filter membrane
integrity test was done by a bubble pressure test. The filter was first rinsed by 10 mL of DI water and
then the inlet of the filter was attached to argon gas and the outlet of the filter was immersed in water.
The argon flow was slowly increased until there was continuous bubbling and the pressure reading
recorded as bubble pressure. Solution pH was measured by spotting the product solution onto a strip
of pH paper. Residual organic solvent analysis was conducted by gas chromatography (GC) analysis
on a Restek Rtx-200 capillary column (60 m × 0.53 mm). Endotoxin level was tested using the LAL
test on the Endosafe-PTS device (Charles River Laboratories, Charleston, SC, USA). After decay of
radioactivity, post-release sterility tests were performed by incubation of the final product solution with
culture media for 14 days. The residual K2.2.2 test was done by visually comparing the spotted sample of
product solution with a standard solution of K2.2.2 on the same TLC plate after development and iodine
staining. Radionuclide identity was confirmed by measuring the half-life of [18 F]5. Chemical purity,
radiochemical purity, and specific activity of [18 F]5 were determined by HPLC analysis of the final
product solution using the conditions described above. The identity of the labeled compound [18 F]5
was confirmed by co-injection of the product solution with the reference standard 5. Stability tests for
[18 F]5 from both manual and automated radiosynthesis methods were performed at 2, 4, and 6 h after
the end of synthesis by checking the radiochemical purity using the same analytical HPLC conditions.
4.4. Animal Preparation and Surgery
A healthy beagle dog (11 kg) was sedated with propofol (7.5 mg/kg) via intravenous injection
in the foreleg cephalic vein, and then intubated for mechanical ventilation (Veturi; Cardiopulmonary
Corp., Milford, CT, USA) and anesthesia maintenance. Anesthesia was maintained with 1%–3%
isoflurane, 65% nitrous oxide, and 35% oxygen. The level of anesthesia was determined by monitoring
heart rate, blink reflex and jaw tone. Blood gases, electrolytes (VetStat Electrolyte and Blood Gas
Analyzer, IDEXX Laboratories Inc., Westbrook, ME, USA) and hematocrit were serially measured

Molecules 2016, 21, 1696

10 of 11

throughout the study and ventilator settings were adjusted accordingly to maintain physiological
conditions. Cardiac rhythm and rate (ECG), oxygen saturation (pulse oximeter), and body temperature
(rectal temperature probe) were monitored via a Phillips InteliVue MP50 monitor. A small femoral
cut-down (4 cm) was performed and a 6F introducer sheath was placed in the right femoral artery to
monitor pressure.
4.5. Animal PET/CT Imaging
The dog was placed feet first in a lateral decubitus position for imaging on a Siemens mCT
PET/CT scanner. ECG leads and a respiratory gating belt were placed for cardiac and respiratory
motion corrections, respectively. Prior to the PET scan, a non-contrast CT scan (120 kV, 11 mAs, 2.0 mm
slices) was performed during temporary detachment from the ventilation to limit respiratory motion
artifact. Following the CT scan, 0.185 GBq of [18 F]DHMT was injected via the femoral vein and a 2 h
dynamic PET scan was performed.
All animal experiment protocols were approved by the Institutional Animal Care and Use
Committees at the Yale University School of Medicine (protocol: 2014-11623), according to the guiding
principles of the American Physiological Society on research animal use.
5. Conclusions
We reported an optimized and automated radiosynthesis of [18 F]DHMT for large-scale production.
This study is the first demonstration to produce 2-[18 F]fluoroethyl azide with an automated module,
which can be used to produce a variety of other PET tracers through click chemistry. The production
process for [18 F]DHMT yielded the product in reliably high radiochemical purity and quality suitable
for human use. PET studies demonstrated the feasibility of using [18 F]DHMT for imaging of the heart
in a canine model.
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